GlassScriptPhysician profile
Ambika Bali
NPI 1427096478
$1,714.67
in general payments reported to CMS, 2019-2025
21 companies · $488 in 2025
The $488 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $18.95 · 2021: $210 · 2022: $106 · 2023: $283 · 2024: $380 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,151.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $416.87 | 2021-2025 | Stelara, Simponi Aria, Simponi |
| Gilead Sciences, INC. | $187.79 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $166.30 | 2024-2025 | Vowst, Zenpep |
| Intercept Pharmaceuticals, INC. | $163.98 | 2019-2024 | |
| Qol Medical, LLC | $127.42 | 2024-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.80 | 2019-2025 | Xifaxan, Trulance |
| Celltrion USA INC. | $67.20 | 2024-2025 | Vegzelma |
| Abbvie INC. | $66.20 | 2023-2024 | Avycaz |
| Madrigal Pharmaceuticals | $57.96 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $47.63 | 2024 | Eohilia, Entyvio |
| Ferring Pharmaceuticals INC. | $47.25 | 2023-2025 | Rebyota |
| Exact Sciences Corporation | $46.82 | 2024-2025 | Cologuard Collection Kit |
| Redhill Biopharma INC. | $40.75 | 2020-2024 | Talicia |
| Echosens North America, INC. | $30.16 | 2024 | Fibroscan |
| Shire North American Group INC | $24.88 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $24.83 | 2025 | Qsymia |
| Alnylam Pharmaceuticals INC. | $21.80 | 2023 | Givlaari |
| Lucid Diagnostics INC. | $20.21 | 2022 | |
| Intra-Sana Laboratories | $17.66 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Braintree Laboratories, INC. | $16.95 | 2025 | Sutab, Suflave |
| Blueprint Medicines Corporation | $16.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ambika Bali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.